RDs typically help patients on GLP-1 medications focus on eating adequate protein, fiber, and micronutrients to prevent malnutrition and muscle loss
Across four databases, the initial search produced 208 citations
In the Phase 2 trial, retatrutide was given as a once-weekly subcutaneous injection, starting at a low dose and escalating gradually up to 12 mg weekly
Individual variation in gut microbiome composition, diet, and metabolic response to the medication all play a role
The inclusion of oral GLP-1s at $149/month could make these medications even more accessible for patients who prefer a pill over injections
Treatment should be about improving health and quality of life, not about conforming to societal beauty standards or reinforcing harmful weight stigma